Login to Your Account



Synthon to Debut New Focus with HER2-ADC Data at AACR

By Nuala Moran
Staff Writer

Tuesday, April 2, 2013

Following the FDA approvals of the first two antibody-drug conjugates (ADCs), the market is moving forward to develop enhanced products based on linker technologies that will make that new class of biopharmaceutical/small-molecule hybrids safer, more effective and easier to manufacture.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription